ProShares UltraShort Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET +$378 OVER THIS RANGE
Flows are quiet — the past month netted out near zero, while the price has returned -43.0% so far this year. At 0.95% a year it is not the cheapest way in — IJH runs the same ground at 0.05%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
| 1 week | -11.9% |
| 1 month | -22.0% |
| 3 months | -37.0% |
| 6 months | -36.3% |
| YTD | -43.0% |
| 1 year | -61.5% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | +$360 |
| YTD | +$460 |
| 1 year | +$2K |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
Due diligence cuts both ways. These funds sit on the same shelf and beat BIS on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.03% | $97.9B | +$245M | -92bp on fee · +$245M in over the month | Head-to-head |
| IUSG iShares Core S&P U.S. Growth ETF | 0.04% | $33.8B | +$668M | -91bp on fee · +$668M in over the month | Head-to-head |
| IUSV iShares Core S&P U.S. Value ETF | 0.04% | $28.1B | +$103M | -91bp on fee · +$103M in over the month | Head-to-head |
| IVV iShares Core S&P 500 ETF | 0.03% | $900.9B | −$14.2B | -92bp on fee | Head-to-head |
| VOO Vanguard 500 Index Fund | 0.03% | $500.4B | — | -92bp on fee | Head-to-head |